Subcutaneous Versus Intravenous Immunoglobulin for Chronic Autoimmune Neuropathies - A Meta-Analysis

episode

American Association of Neuromuscular & Electrodiagnostic Medicine (AANEM) not yet transcribed

▲ 0

Transcript

This episode hasn't been transcribed yet Upvotes decide what gets transcribed next — 0 so far. Sign in to upvote

Related

recent transcribed audio

Russia’s New Drone Threat Raises Alarms in Ukraine 21 min · 27 Sep 2026 · The MeidasTouch Podcast

FULL SHOW: Evict My House Guest Awkward, Whatcha Doin’ at Oktoberfest + Prison Prank (9/22/26) 55 min · 27 Sep 2026 · Brooke and Jeffrey: Second Date Update

The Inherited Mindset: Firing Your Family’s Financial Beliefs 3 min · 27 Sep 2026 · The Level Up Podcast w/ Paul Alex

The Rise of the AI Moderates 32 min · 27 Sep 2026 · The AI Daily Brief: Artificial Intelligence News and Analysis

NPR News: 09-27-2026 7AM EDT 5 min · 27 Sep 2026 · NPR News Now

7AM ET 09/27/2026 Newscast 3 min · 27 Sep 2026 · Fox News Hourly Update

Report any issue

Source

Recorded27 Jun 2018

Publisheranchor.fm ↗

Handlerec:820507

Show notes

Dr. Speelziek interviews Dr. Kurt Kimpinski and Dr. Luciano Sposato on their article, Subcutaneous versus intravenous immunoglobulin for chronic autoimmune neuropathies. A meta-analysis. High-dose intravenous immunoglobulin (IVIg) is an evidence-based treatment for multifocal motor neuropathy (MMN) and chronic inflammatory demyelinating polyneuropathy (CIDP). Recently, subcutaneous immunoglobulin (SC-Ig) has received increasing attention. The authors performed a meta-analysis of reports of efficacy and safety of SC-Ig versus IVIg for inflammatory demyelinating polyneuropathies.The efficacy of SC-Ig is similar to IVIg for CIDP and MMN and has a significant safety profile. Muscle Nerve 55: 802-809, 2017.

Ask this episode

“What did the council decide on item 42?” — answered with the speaker and the moment.

Sign in